Encouragingly, the immunotherapy for NSCLC has been revolutionized by the introduction of immune checkpoint inhibitors (ICIs) against programmed death protein-1 (PD-1) and its ligand PD-L1 or cytotoxic T-lymphocyte antigen-4 (CTLA-4) [4–6]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.